GlycoNex

GlycoNex FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of GlycoNex (4168.TWO) as of Nov 4, 2026 is 73.49 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 111.99 % — a change of -34.38% (lower).

FCF Conversion

73.49 %

YoY

-34.38%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of GlycoNex is 2025 73.49 % . FCF Conversion Rate (FCF/EBITDA) of GlycoNex was 2024 111.99 % . It decreases by -34.38% lower compared to the previous year.

The GlycoNex FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
57.91 TWD
Jan 1, 2019
73.24 TWD
Jan 1, 2020
90.62 TWD
Jan 1, 2021
85.63 TWD
Jan 1, 2022
80.17 TWD
Jan 1, 2023
116.25 TWD
Jan 1, 2024
111.99 TWD
Jan 1, 2025
73.49 TWD
The GlycoNex FCF Conversion history
YEARFCF ConversionYoY
73.49 %-34.38%
111.99 %-3.66%
116.25 %+45.00%
80.17 %-6.37%
85.63 %-5.51%
90.62 %+23.72%
73.24 %+26.47%
57.91 %-51.93%
120.47 %-52.08%
251.40 %-74.28%
977.38 %+246.80%
281.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GlycoNex Stock analysis

What does GlycoNex do? GlycoNex, Inc. develops anti-cancer monoclonal antibodies and bio-similar drugs, offering licensing for monoclonal antibody targets and carbohydrate antigen and protein drug services. The company targets domestic and Asian markets, distributing its products through these regions. Revenue comes from drug development, licensing agreements, and service provision for antibody targets and related biotech solutions. GlycoNex focuses on anti-cancer monoclonal antibody new drugs and bio-similar drugs, with services including carbohydrate antigen and protein drug related offerings. The firm serves domestic and overseas markets in Asia, generating income from product development, licensing, and specialized biotech services. Its business model relies on developing and commercializing innovative cancer treatments and related services in key Asian markets. The company's revenue streams include the development of anti-cancer monoclonal antibody new drugs, bio-similar drugs, and the licensing of monoclonal antibody targets. Services related to carbohydrate antigen and protein drug solutions are also part of the business, distributed across domestic and Asian markets to generate income from pharmaceutical innovation and biotech service contracts. GlycoNex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GlycoNex stock

FCF Conversion Rate (FCF/EBITDA) of GlycoNex is 73.49 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of GlycoNex changed from 111.99 % to 73.49 %, representing a -34.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) GlycoNex since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s GlycoNex with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — GlycoNex

All Key Metrics — GlycoNex